Spark Investment Management LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,100 shares of the company’s stock after selling 14,100 shares during the period. Spark Investment Management LLC’s holdings in IDEXX Laboratories were worth $6,739,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of IDXX. Zions Bancorporation bought a new stake in IDEXX Laboratories during the third quarter worth approximately $162,000. Benjamin F. Edwards & Company Inc. boosted its holdings in IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. SignalPoint Asset Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $200,000. Ledyard National Bank boosted its holdings in IDEXX Laboratories by 58.9% during the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after buying an additional 480 shares in the last quarter. Finally, BB&T Securities LLC bought a new stake in IDEXX Laboratories during the third quarter worth approximately $213,000. Hedge funds and other institutional investors own 86.02% of the company’s stock.
In related news, Director Lawrence D. Kingsley bought 1,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was bought at an average price of $178.05 per share, for a total transaction of $178,050.00. Following the transaction, the director now directly owns 4,558 shares in the company, valued at $811,551.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William T. End sold 4,000 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total transaction of $737,920.00. Following the completion of the sale, the director now owns 41,256 shares of the company’s stock, valued at approximately $7,610,906.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,762 shares of company stock valued at $15,940,404. Insiders own 2.77% of the company’s stock.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. During the same quarter in the prior year, the firm earned $0.58 EPS. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. research analysts forecast that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.
Several equities research analysts recently commented on IDXX shares. BidaskClub downgraded shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America upped their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price target for the company. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $194.00.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.